New study aims to decode HER2+ breast cancer for personalized treatment
NCT ID NCT07187752
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will enroll over 1,000 women with HER2-positive breast cancer to analyze the molecular characteristics and subtypes of their tumors. Participants will receive standard pre-surgery treatment with trastuzumab, pertuzumab, and chemotherapy. The goal is to identify which subtypes respond best to this therapy, potentially paving the way for more personalized treatment approaches.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trastuzumab and pertuzumab (biosimilars) plus chemotherapy
- What this could lead to
- If successful, this could help doctors better match HER2+ breast cancer treatments to individual patients based on their tumor's molecular profile.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?